Valneva submits label extension application for its chikungunya vaccine, ixchiq®, to the u.s. fda

To potentially include adolescents and antibody persistence up to two years saint herblain (france), november 26, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that it has submitted a label extension application to the u.s. food and drug administration (fda) to potentially extend the use of its chikungunya vaccine ixchiq®, which is currently approved in adults, to adolescents aged 12 to 17 years. the application also includes adding the two-year antibody persistence data to the product label, which is a key differentiator for ixchiq®.
VALN Ratings Summary
VALN Quant Ranking